PCa specimens; paired non-tumor tissues; tumor tissues; xenografts
DU145; PC3; NCI-H660; RWPE-1; THP-1
cell line-derived xenograft
proliferation (promotes); migration (promotes); EMT (promotes); metastasis (promotes); mRNA stability (promotes); immune regulation (promotes); macrophage polarization (promotes); other pathway/process (promotes)
Back-Splice Junction PCR / divergent primers PCR; RNase R Treatment; Sanger Sequencing; circRNA-seq; Actinomycin D / DRB Stability Assay; RT-qPCR; FISH / smFISH; IF (Immunofluorescence); IHC (Immunohistochemistry); Nuclear-Cytoplasmic Fractionation; Clinical Sample Validation; RIP (RNA Immunoprecipitation); RNA Pull-Down; Co-IP; Luciferase Reporter Assay; Transfection; CCK8; Colony Formation Assay; Transwell Assay; Wound Healing Assay; Flow Cytometry(Non-apoptosis/cycle); In Vivo Animal Model; Western Blot; Bioinformatics Analysis
circ_0094606 was highly expressed in 70% of PCa patients and was proposed as a potential novel effective target for PCa treatment.
hsa_circ_0094606/circ_0094606 is up-regulated in prostate cancer tissues and cells. It promotes PCa proliferation, migration, EMT, xenograft growth, and macrophage M2 polarization by binding PRMT1, enhancing PRMT1-mediated ILF3 arginine methylation, and increasing IL-8 mRNA stability/expression. The study proposes circ_0094606 as a potential therapeutic target for PCa.
0.8856
Hsa_circ_0094606 promotes malignant progression of prostate cancer by inducing M2 polarization of macrophages through PRMT1-mediated arginine methylation of ILF3.
combined biological and clinical study